OncoDEEP offers the most complete and comprehensive combination of DNA/RNA/proteins tests. This approach is supported by the fact that most treatment decisions (93.4%) are made based on the combination of several analyses (JF Laes et al., Oncotarget 2018;9; 29).
OncoDEEP analyses solid biopsies by combining next-generation sequencing (313 genes), IHCs to study protein expression and additional tests. This complete tumour profiling allows to predict patient response to approved or experimental hormonal therapies, targeted drugs, immunotherapies and chemotherapies. The NGS panel is accurately designed according to oncologists’ needs in their current practice. Importantly, it includes an accurate determination of MSI, TMB and LOH. The NGS panel is regularly updated based on new findings reported in the literature in order to provide patients with the most cost-effective solution.
NRTK testing is included in OncoDEEP for some cancer types, and it can be ordered also as a standalone test.
Our immunogram combines five different biomarkers for predicting clinical benefit of immune checkpoint inhibitors (ICIs): PD-L1 protein expression (FDA-approved marker), TMB, CD8+ T-cell infiltration, MSI (FDA-approved marker) and gene alterations leading to sensibility or resistance to ICIs.
OncoDNA publishes regularly in peer-reviewed international journals.
Here below you will find a selection of key publications supporting our clinical expertise in precision oncology.
Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience ... [READ MORE]
- Annals of Clinical Oncology 2019
The clinical impact of using complex molecular profiling strategies in routine oncology practice ... [READ MORE]
- Oncotarget 2018
Ordering a solution is very simple: Just log in to OncoSHARE and select the solution(s) you are interested in. If you do not have a kit for sample collection, we will send you one. After sample processing and interpretation by our expert team, an interactive report will be available for you on OncoSHARE. You can review it, and also share it with your colleagues.
After sample processing and interpretation by our expert team, a comprehensive report will be available for you on our platform OncoSHARE. In a simple and interactive manner, it will help you with the selection of the most appropriate treatments based on the unique signature of your patient's tumour. Moreover, you can share the report with your colleagues.
If your question is not included in the list above or you would like more information about our solutions, please contact us at email@example.com. Our Patient and Scientific Support teams are available to answer your questions from Monday to Friday. You can also reach us through the chat (icon at the bottom right corner of current window).
OncoSTRAT&GO is an integrated approach that combines the analyses of a solid biopsy (by next-generation sequencing (313 genes), IHCs and additional tests) with the analysis of a blood biopsy. The blood profiling focuses either on the circulating tumor DNA (for deciphering tumor heterogeneity) or in DNA from blood cells (for studying specific germline gene alterations related to BRCAness phenotype that are challenging to detect in FFPE samples). OncoSTRAT&GO establishes a complete genetic profile of the tumor, which can be used to identify sensitivity or resistance to targeted therapies, hormonal therapies, chemotherapies and immunotherapies.Read more
OncoSELECT is a fast and minimally invasive analysis of circulating tumor DNA from a blood sample. It is the perfect solution to identify therapeutic options for cancer patients not able to have their tumor biopsied or whose biopsy is too old. It can be used as a tool to detect treatment resistance to targeted and hormonal therapies (before first-line to check the heterogeneity of the disease, or during/after treatment to check for acquired resistance mutations), as well as for monitoring cancer progression.Read more
OncoTRACE by OncoDNA is a test based on the analysis of circulating tumor DNA in blood. It is used to monitor the progression of the tumor (burden of the disease) and to detect lack of response or resistance to treatment as soon as it appears.
This assay is customized for each patient, as it analyses variants previously identified in the tumour of the patient.
In 2013, OncoDNA became the first company to launch a personalised liquid biopsy test.Read more